Pharmacist-Led PEP/PrEP

Target Audience

The educational design of this activity addresses the needs of clinical and community pharmacists involved in the care of patients at risk for HIV infection.

Program Overview

Despite extensive HIV prevention efforts, rates of new diagnoses have not declined to the projected targets needed to end the HIV epidemic. Pharmacists have a critical role in the initiative to end the HIV epidemic and, therefore, must stay up to date on guidelines and protocols for HIV preexposure and postexposure prophylaxis (PrEP and PEP, respectively). This comprehensive electronic/downloadable monograph was developed specifically to support evolving and expanding needs of pharmacists. Recently, the pharmacy scope of practice has broadened in many states in the US, and this continuing education activity provides the necessary clinical information for initiating and monitoring PrEP and PEP treatment in the pharmacy setting. This monograph provides the education pharmacists need to incorporate the Centers for Disease Control and Prevention (CDC) 2021 Updated PrEP Clinical Practice Guidelines into their daily practice. In addition, with 2.0 contact hour(s) (0.20 CEUs) from the Accreditation Council for Pharmacy Education, this monograph addresses all content necessary for pharmacists wishing to become PrEP and PEP providers in order to fulfill most state board of pharmacy training requirements, such as:

• HIV epidemiology and burden
• Pharmacology, safety, and efficacy of HIV medications used for PrEP and PEP (including oral tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), oral tenofovir alafenamide (TAF)/FTC, and cabotegravir long-acting injectable (CAB LAI))
• Assessment of sexual health and HIV risk
• Patient counseling
• Screening for HIV and sexually transmitted infections (STIs) and laboratory testing to determine PrEP/PEP eligibility
• 2021 CDC updated PrEP clinical practice guidelines for PrEP eligibility, prescribing, and management
• Clinical practice guidelines for nonoccupational PEP (nPEP) eligibility, prescribing, and management
• In-pharmacy implementation of both oral and LAI PrEP
• Trauma-informed care

Educational Objectives

After completing this activity, the participant should be better able to:

• Summarize the professional parameters and current needs for pharmacy-based direct delivery of PEP and PrEP services
• Identify a patient’s potential risk of HIV acquisition in a nonthreatening, nonjudgmental manner
• Determine patients’ PEP/PrEP clinical eligibility based on the 2021 CDC PrEP Updated Clinical Guidelines, medical history, and appropriate laboratory testing
• Implement PEP/PrEP management services, including appropriate drug selection, initiation, and ongoing monitoring
• Identify infrastructure needs for in-pharmacy implementation of PEP/PrEP prescribing

Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Credit Designation

Global Education Group designates this continuing education activity for 2.0 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-24-021-H02-P)

This is an application-based activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, read the monograph in its entirety, score at least 70% on the posttest, and complete the program evaluation. Pharmacists must check CPE monitor for their credit within 60 days of activity completion.

Fee Information& Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Relevant Financial Relationships

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Arsalan "RC" Shah, PharmD, MBA: Speakers' Bureau: AbbVie, Gilead Sciences, Inc.

Melissa Badowski, PharmD, MPH, FCCP, BCIDP, BCPS: Nothing to disclose

The planners and managers at Global Education Group and Integritas Communications have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirement